Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis's Ofatumumab Pursues Entrenched Competitors In MS

Executive Summary

Novartis’s anti-CD20 MS candidate, ofatumumab, shows promise in initial findings from the ASCLEPIOS Phase III studies, but more details are needed to show how it stacks up against Sanofi’s Aubagio, and ultimately against Roche’s Ocrevus.

You may also be interested in...



Novartis' Kesimpta Goes Up Against Roche's Ocrevus In MS

The anti-CD20 monoclonal antibody was approved by the US FDA for relapsing multiple sclerosis, bringing a new treatment to the crowded therapeutic area – with the benefit of self-administration. 

Novartis In Line For Ofatumumab MS Approval In June

Novartis’s cancer drug has now been filed for multiple sclerosis in the US, armed with a priority review, and in Europe.

Novartis Makes Mayzent Case With More MS Data

Presentations at ECTRIMS highlight the recently approved pill's effects on disability and cognition.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel